Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Express Scripts wants blood disorder gene therapies exclusively

Express Scripts Holding Co. (NASDAQ:ESRX) said it is in discussions with gene therapy companies to become the exclusive distributor for blood disorder treatments, which could enable the PBM to test a payment-over-time reimbursement model.

The PBM said the companies include BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and bluebird bio Inc.

Read the full 471 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers